AMAG proposes $150 million note deal

AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) proposed to raise $150 million through the sale of senior convertible notes due 2019 in an offering underwritten by JPMorgan and Morgan Stanley. AMAG markets Feraheme ferumoxytol to treat iron deficiency anemia in adults with chronic kidney disease (CKD). Last month, FDA issued a complete response letter for an sNDA from AMAG seeking to expand the label for the IV iron replacement therapy to include treatment of all adults with iron deficiency anemia who have failed or could not tolerate oral iron treatment (see BioCentury Extra, Jan. 22). ...